Twelve monoclonal antibodies neutralizing the CVS strain of rabies virus were used to characterize antigenic site II of the viral glycoprotein. Nineteen antigenic mutants resistant to neutralization by some of these antibodies were selected; some continued to normally or partially bind the antibody, whereas others did not. Mutations conferring resistance to neutralization by site II-specific monoclonal antibodies were localized into two clusters, the first between amino acids 34 and 42 (seven groups of mutants) and the second at amino acids 198 and 200 (three groups of mutants). Two intermediate mutations were identified at positions 147 and 184. Four mutations resulted in reduced pathogenicity after intramuscular inoculation of the virus in adult mice. One of the mutants, M23, was 300 times and the others were 10 to 30 times less pathogenic than CVS. In three cases the attenuated phenotype was related to an important modification of antigenic site II, whereas the other known antigenic sites were unchanged.
Rabies virus is composed of a nucleocapsid containing a negative-strand RNA molecule (around 12,000 nucleotides long) wrapped into three protein species (L, Ml, and N) and surrounded by a lipid bilayer associated with two protein species (M2, which is internal, and G, which is a glycosylated transmembrane). In addition to the five viral proteins, some contaminants of cellular origin such as actin (24) are included in the virion. The glycoprotein (which is the only protein external to the virion) plays an important role in viral pathogenesis: it is responsible for the recognition of specific cell surface receptors, thus controlling at least one aspect of viral tropism. It induces the synthesis of neutralizing antibodies (32) , and after presentation by infected cells it is recognized by cytotoxic T cells (6) .
Antigenic characteristics of the protein have been studied by using mutants resistant to neutralization by monoclonal antibodies (MAbs) selected as described by Seif et al. (28) . One major site recognized by around 70% of the available MAbs has been described by Lafon et al. (20) (site II). The presence of another site (site III) recognized by 20% of the MAbs and several minor sites has also been demonstrated (20) .
We have previously shown that site III is linear, extending from amino acids 330 to 340 (28) . Some mutants affected in site III have lost virulence for adult animals such as mice, foxes, and various kinds of rodents (7, 8, 26) . Further investigations located the mutation at amino acid 333, an arginine replaced by either glutamine, glycine, or isoleucine (12, 28) . This mutation completely modified the host range spectrum of the virus (18) .
The above results and others concerning influenza virus (5), reovirus (17, 30) , coronavirus (9, 14) , and mumps virus (22) suggested that antigenic sites on external proteins of virions are crucial regions which interact not only with antibodies but also with other host molecules such as cellular receptors. It is therefore of special interest to study the effect on pathogenicity of mutations modifying a major ( Nucleotide sequence analysis. The genomic RNA was obtained from 150 to 200 ,ug of purified virion, after digestion with proteinase K, followed by a phenolic extraction as previously described (28) . The dideoxy chain-terminator method (27) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis of proteins was performed as previously described (19) . Slab gels were stained with Coomassie brillant blue or by the silver staining method (25) .
RESULTS
Isolation and characterization of site II-specific antigenic mutants. Twelve neutralizing MAbs recognizing site II of the viral glycoprotein were used in this study. They have been classified as site II specific because they failed to neutralize representative site II mutants but retained their capability to neutralize mutants at other sites. Five of them were used to select antigenic mutants, and then their resistance to the other antibodies was determined. A mutant was considered fully resistant when its titer in the presence of antibody was at least 50% of that observed without antibody. The mutant was considered slightly resistant when the titer after incubation with antibody was between 50 and 10% of the control. Below 10% of the control, the mutant was considered sensitive. All class II mutants were still neutralized by the specific MAbs for the antigenic site III of the CVS strain (data not shown); no overlapping of antigenic sites II and III was observed. All mutants were at least resistant to the MAb used for their selection, even though two of them were only slightly resistant: K18 had 10% resistance to MAb 101.1, and M23 had 30% resistance to MAb 25A1.
The mutants were classified into 12 different groups according to their pattern of resistance to the 12 MAbs (Fig. 1) . Resistance varied from being restricted to a single MAb (K14) to including almost every site II-specific MAb (A17 and J25). Seven groups were represented by a single mutant. Five groups contained two or more mutants. In this case two or three representatives were retained for further studies.
Fixation of MAbs on the mutants. The fixation of MAbs on the mutants and on CVS was studied with the enzyme-linked immunosorbent assay, using the same amount of dried virus as the antigen. As expected, the fixation of a given MAb on mutants which were still neutralized was similar to that observed on CVS. Partial neutralization of a mutant usually correlated with a normal fixation of the MAb; the only exception was the weak fixation of MAbs 231.22 and 24A1 on mutant P3 (Fig. 1) .
For mutants fully resistant to neutralization all possible situations were observed: either the mutants continued to fix the MAb normally (for instance, MAb 45C5 with mutants of groups 4, 5, and 11), there was no fixation at all (45C5 with mutants of group 2), or the fixation was intermediate (45C5 with mutants of groups 3 and 10). Similarly, for a given antibody, all of these situations could be found (Fig. 1) .
To determine whether the fixation occurred on live virus the following experiment was performed. Virus, purified and concentrated by a rapid procedure which preserves infectivity, was incubated with antibody and sedimented through a glycerol pad. Pellets were suspended in sodium dodecyl sulfate buffer and analyzed on polyacrylamide gels. As a control the virus was incubated with an antinucleocapsid MAb (21A6) which would fix only on disrupted virions. In this latter case, no fixation was observed, which indicated that most of the pelleted virions were indeed intact (Fig. 2) . The fixation of MAb 45C5 on CVS, A17, and K2 was similar, although both mutants were resistant to neutralization. By comparison only partial fixation of MAb 45C5 on A17 was found in the enzyme-linked immunosorbent assay (Fig. 1) .
The intensity of light and heavy immunoglobulin bands was compared with that of viral proteins on Coomassie blue-stained gels (data not shown). The results suggested that one molecule of immunoglobulin was fixed on each glycoprotein of the virus.
Experiments with MAbs 7B1 and PVK were more difficult to quantify because their heavy and light chains migrated closer to N and M2. The fixation of PVK on CVS and K2 was similar; it was notably reduced on A17 (which was resistant to this antibody). The fixation of 7B1 was similar on the three viruses (Fig. 2) .
With the exception of MAb 45C5 with A17, results obtained with dried or live viruses were very similar. Both methods indicate that resistance to neutalization is not necessarily correlated with a lack of fixation of a given MAb.
Electrophoretic pattern of the mutant. It has been previously shown that an amino acid substitution at position 198 results in complete loss of the GII form of the glycoprotein (34) . We found the same result for group 11 and only a partial loss for group 10, both affected at lysine 198 the electrophoretic profile of A17 is shown in Fig. 2 . Mutants of the other groups had the two forms of the glycoprotein in normal amounts (compare K2 and CVS in Fig. 2) .
Localization of the mutation of class II antigenic mutants. The nucleotide sequence of CVS parental and mutant glycoproteins has been partially or totally established by the dideoxy chain-termination method. The deduced amino acid sequence of the parental glycoprotein is shown in Fig. 3 . Three differences appeared between this sequence and that published by Yelverton et al. (35) : at position 36, an isoleucine instead of a threonine; at position 122, a leucine, instead of a valine, like in the ERA strain; and at position 156, a glycine instead of a serine, like in the PV strain (1, 31) .
For each antigenic site II mutant, a length of the gene was sequenced; we found only one base substitution which in any case resulted in an amino acid change ( Table 1 (8) . To detect any difference between the site II mutants and the CVS parental strain the pathogenicity of representative site II mutants was studied after intramuscular inoculation. Serial dilutions of the virus were inoculated into five adult mice, and the survival of animals was followed (Fig. 4) . By this route of inoculation, the 50% lethal dose was equal to 350 PFU for CVS; for J19, A17, P3, and J25, respectively, it was equal to 3.5 x 103, 8.9
X 103, 9.3 x 103, and 10.7 x 103 PFU (i.e., 10 to 30 times more), and for M23 it was equal to 9.3 x 104 PFU (300 times more). Representatives of other site II groups of mutants were as pathogenic as the parental CVS strain (K2 in Fig. 3 ).
DISCUSSION
We studied the structure of the main antigenic site of the rabies glycoprotein (site II) by using a collection of mutants resistant to neutralization by several MAbs directed to this site. Amino acid substitutions of representative mutants We are currently investigating which of these steps is blocked in the case of rabies and the possible modifications of the virus induced by the fixation of antibodies.
We found that five mutants were substantially less pathogenic than the CVS parental strain (by a factor of 10 or 100). In mutant J17 the mutation is at one extremity of the first cluster, but site II is deeply modified in the four others.
The structure of antigenic site II is very different from that of site III, which expands linearly from amino acids 330 to 340 (28) . This region was previously implicated in the recognition of specific receptors present on nerve endings (18) . The The fact that some of site II antigenic mutants, especially those affected in amino acid 198, are less pathogenic for adult animals is certainly interesting. It could reveal another type of interaction between the virus and the host, either at the beginning or at the end of the infection, when the virus has invaded the nervous system of the host and is disseminating in some non-nervous specialized cells (23) . As expected antigenic mutants with modified pathogenicity are promising tools to study the multiple aspects of viral virulence.
